Peptides for Immune Decline (Immunosenescence)

Immunosenescence — the gradual decline of immune function with age — is driven by thymic involution (the thymus shrinks with age, producing fewer new T-cells), accumulating senescent immune cells, and gut barrier decline (70% of immune tissue is gut-associated). The Midas Protocol targets immune aging through: Thymosin Alpha-1 (directly compensates for thymic decline, approved in 35+ countries as Zadaxin), FOXO4-DRI (clears senescent immune cells and their inflammatory SASP), and BPC-157 (gut barrier repair to support gut-associated lymphoid tissue).

The Multi-Pathway Advantage

Single-compound approaches address one mechanism. The Midas Longevity Protocol addresses immune decline (immunosenescence) from multiple angles simultaneously — repair, protection, regeneration, and senescent cell clearance. This is why a 12-compound protocol outperforms individual peptides for age-related conditions.